360 related articles for article (PubMed ID: 15864268)
41. Rho kinases in cardiovascular physiology and pathophysiology.
Loirand G; Guérin P; Pacaud P
Circ Res; 2006 Feb; 98(3):322-34. PubMed ID: 16484628
[TBL] [Abstract][Full Text] [Related]
42. A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present).
Martinez-Gualda B; Schols D; De Jonghe S
Expert Opin Ther Pat; 2021 Oct; 31(10):911-936. PubMed ID: 33971786
[TBL] [Abstract][Full Text] [Related]
43. NSAIDS and Alzheimer's disease: it's only Rock and Rho.
Burton A
Lancet Neurol; 2004 Jan; 3(1):6. PubMed ID: 14700055
[No Abstract] [Full Text] [Related]
44. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II.
Feng Y; Cameron MD; Frackowiak B; Griffin E; Lin L; Ruiz C; Schröter T; LoGrasso P
Bioorg Med Chem Lett; 2007 Apr; 17(8):2355-60. PubMed ID: 17368019
[TBL] [Abstract][Full Text] [Related]
45. Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives.
Xie Y; Yue L; Shi Y; Su X; Gan C; Liu H; Xue T; Ye T
J Med Chem; 2023 Apr; 66(7):4342-4360. PubMed ID: 36940432
[TBL] [Abstract][Full Text] [Related]
46. Increasingly selective pharmacologic targets in cardiovascular disease.
Paoletti R; Cignarella A
Curr Atheroscler Rep; 2007 Aug; 9(2):89-90. PubMed ID: 17877914
[No Abstract] [Full Text] [Related]
47. A focus on Rho/ROCK signaling pathway: An emerging therapeutic target in depression.
Hanifa M; Singh M; Randhawa PK; Jaggi AS; Bali A
Eur J Pharmacol; 2023 May; 946():175648. PubMed ID: 36894049
[TBL] [Abstract][Full Text] [Related]
48. Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases.
Wang Q; Song LJ; Ding ZB; Chai Z; Yu JZ; Xiao BG; Ma CG
Neural Regen Res; 2022 Dec; 17(12):2623-2631. PubMed ID: 35662192
[TBL] [Abstract][Full Text] [Related]
49. ROCKs as immunomodulators of stroke.
Wang QM; Liao JK
Expert Opin Ther Targets; 2012 Oct; 16(10):1013-25. PubMed ID: 22925075
[TBL] [Abstract][Full Text] [Related]
50. The role of the Rho/ROCK signaling pathway in inhibiting axonal regeneration in the central nervous system.
Liu J; Gao HY; Wang XF
Neural Regen Res; 2015 Nov; 10(11):1892-6. PubMed ID: 26807132
[TBL] [Abstract][Full Text] [Related]
51. Modifying protein misfolding.
Jones D
Nat Rev Drug Discov; 2010 Nov; 9(11):825-7. PubMed ID: 21030987
[No Abstract] [Full Text] [Related]
52. New technologies deliver in treating neurological diseases.
Singer E
Nat Med; 2004 Dec; 10(12):1267. PubMed ID: 15580235
[No Abstract] [Full Text] [Related]
53. ROCKing Regeneration: Rho Kinase Inhibition as Molecular Target for Neurorestoration.
Tönges L; Koch JC; Bähr M; Lingor P
Front Mol Neurosci; 2011; 4():39. PubMed ID: 22065949
[TBL] [Abstract][Full Text] [Related]
54. What Is the Role of the Rho-ROCK Pathway in Neurologic Disorders?
Benarroch E
Neurology; 2023 Sep; 101(12):536-543. PubMed ID: 37722862
[No Abstract] [Full Text] [Related]
55. Microglia--a therapeutic target in neurological diseases and disorders.
Kaur C; Ling EA
CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):719. PubMed ID: 24047518
[No Abstract] [Full Text] [Related]
56. Calmodulin kinase II as a target for inhibition in cardiac disease.
Doggrell SA
Expert Opin Ther Targets; 2005 Dec; 9(6):1319-21. PubMed ID: 16300478
[No Abstract] [Full Text] [Related]
57. New frontiers in G protein-coupled receptor regulation of neurological disorders.
Maudsley S
CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):525. PubMed ID: 20632974
[No Abstract] [Full Text] [Related]
58. The neuroscientist's melting pot: immunology, cell transplantation and other delivery systems, and enlightenment of disease etiology and treatment.
Eve DJ; Sanberg PR
Neurotox Res; 2008; 13(3-4):281-90. PubMed ID: 18522907
[TBL] [Abstract][Full Text] [Related]
59. Different targets of anti-glucocorticoid treatment have been proposed, acting at supra-hypothalamic, HPA axis, glucocorticoid receptor and post-receptor levels.
Di Marzo V
Recent Pat CNS Drug Discov; 2013 Apr; 8(1):1. PubMed ID: 23565885
[No Abstract] [Full Text] [Related]
60. Nanotherapeutics for Neurological Disorders.
Baboota S; Ali J
Curr Pharm Des; 2020; 26(19):2193-2194. PubMed ID: 32563238
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
